A Multicenter Phase 2 Open-Label, Single-Arm, Prospective, Interventional Study of Plasma-Derived Factor VIIIIVWF Alphanate in Immune Tolerance Induction Therapy in Subjects with Congenital Hemophilia A.
Phase of Trial: Phase II
Latest Information Update: 03 Jan 2018
At a glance
- Drugs Factor VIII/von Willebrand factor (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Sponsors Grifols
- 27 Dec 2017 Planned initiation date changed from 1 Sep 2017 to 1 Dec 2017.
- 12 Sep 2017 Planned initiation date changed from 1 Jun 2017 to 1 Sep 2017.
- 04 Aug 2016 New trial record